(Q51717725)

10 April 2018

title

Vagus nerve stimulation for pharmacoresistant epilepsy: clinical symptoms with end of service. (English)

1 reference

10 April 2018

author name string

Tatum WO 4th

1

1 reference

10 April 2018

Ferreira JA

2

1 reference

10 April 2018

Benbadis SR

3

1 reference

10 April 2018

Heriaud LS

4

1 reference

10 April 2018

Gieron M

5

1 reference

10 April 2018

Rodgers-Neame NT

6

1 reference

10 April 2018

Vale FL

7

1 reference

10 April 2018

publication date

1 February 2004

1 reference

10 April 2018

published in

Epilepsy Behavior

1 reference

10 April 2018

volume

5

1 reference

10 April 2018

issue

1

1 reference

10 April 2018

page(s)

128-132

1 reference

10 April 2018

New antiepileptic drugs: into the new millennium

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.10.014

New horizons in the development of antiepileptic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.10.014

Early identification of refractory epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.10.014

Vagus nerve stimulation therapy summary: five years after FDA approval

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.10.014

Therapeutic mechanisms of vagus nerve stimulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.10.014

Vagus nerve stimulation, side effects, and long-term safety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.10.014

Adverse events in children receiving intermittent left vagal nerve stimulation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.10.014

Long-term treatment with vagus nerve stimulation in patients with refractory epilepsy. The Vagus Nerve Stimulation Study Group E01-E05.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.10.014

Vagus nerve stimulation therapy, epilepsy, and device parameters: scientific basis and recommendations for use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.10.014

Analysis of direct hospital costs before and 18 months after treatment with vagus nerve stimulation therapy in 43 patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.10.014

Prognostic factors affecting long-term retention of topiramate in patients with chronic epilepsy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.10.014

Vagus nerve stimulation (VNS) for major depressive episodes: one year outcomes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.10.014

10.1016/J.YEBEH.2003.10.014

7 January 2021

Identifiers

DOI

1 reference

10 April 2018

1 reference

10 April 2018